Lactobacillus salivarius REN inhibit rat oral cancer induced by 4-nitroquioline 1-oxide

Menée sur des rats, cette étude montre que le Lactobacillus salivarius REN, un nouveau probiotique récemment isolé, peut inhiber la carcinogenèse de la cavité buccale

Résumé en anglais

Despite of significant advances in cancer treatment, cancer related mobility and mortality are still rising. Alternative strategies such as cancer prevention thus become essential. Probiotics represent an emerging option for cancer prevention, but studies are limited to colon cancers. The efficiency of probiotics in the prevention of other cancers and the correlative mechanism remains to be explored. A novel probiotics Lactobacillus salivarius REN was isolated from centralians at Bama of China, which showed highly potent anti-genotoxicity in an initial assay. 4-nitroquioline 1-oxide (4NQO)-induced oral cancer models was introduced to study the anti-cancer activity of L. salivarius REN in vivo. The results indicated that oral administration of probiotic L. salivarius REN or its secretions could effectively suppressed 4NQO-induced oral carcinogenesis in the initial and post-initial stage and the inhibition was in a dose-dependent manner. A significant decrease of neoplasm incidence (65% to 0%) was detected in rats fed with the high dose of L. salivarius REN (5×1010 CFU/kg bw/day). In vivo evidences indicated that the probiotics inhibited 4NQO-induced oral cancer by protecting DNA against oxidative damage and down regulating Cyclooxygenase (COX)-2 expression. L. salivarius REN treatment significantly decreased the expression of proliferating cell nuclear antigen (PCNA), and induced apoptosis in a dose-dependent manner. Our findings suggest that probiotics may act as potential agents for oral cancer prevention. This is the first report demonstrating the inhibitory effect of the probiotics on oral carcinogenesis.